Open Orphan’s hVIVO opens a new quarantine clinic in East London

Open Orphan plc (LON:ORPH), a rapidly growing specialist pharmaceutical services contract research organization (CRO) and world leader in vaccine and antiviral testing using human challenge clinical trials, has announced that hVIVO, part of Open Orphan plc, has opened a new quarantine clinic in East London. The new site is based in Whitechapel, directly opposite the Queen Mary BioEnterprise Innovation Centre which houses hVIVO’s 24 bedroom unique state-of-the-art FluCamp site and the recently opened new street-level volunteer screening centre.  The Whitechapel Clinic will act as an extension of hVIVO`s current QMB site. 

The converted 26-bedroom former boutique hotel, which will be known as the Whitechapel Clinic, has the capacity for up to 19 quarantine rooms and will be used as an additional unit for human challenge trials and volunteer recruitment screening. The quarantine rooms are located across three floors of the former hotel, with each level fully converted  to include a nurses station on each floor.

The new site, like QMB, will follow the highest safety standards to deliver each clinical study and volunteer screening visit. Of the 19 rooms, 8 rooms on a single floor are flexible use clinic rooms, meaning they can be used as either quarantine bedrooms for challenge studies or for volunteer screening visits. Each room at the facility has been fully repurposed to the highest standard, with all volunteer rooms equipped with an en-suite bathroom, TV, wardrobe, and tea & coffee making facilities. This will provide a comfortable space for volunteers during studies. The Whitechapel Clinic, like QMB, is also equipped with a 24-hour security presence and a working hour reception desk.

Cathal Friel, Exexcutive Chairman of Open Orphan plc commented: “Our newest quarantine unit greatly increases our capacity to facilitate hVIVO’s pipeline of upcoming studies. Our QMB clinic is now close to full capacity until December 2021, and as such, the newly renovated, state of the art Whitechapel Clinic will allow us to increase our study capacity substantially in the year ahead.

“We have leased the entire former Whitechapel Hotel and managed to convert the space on a very cost efficient basis which is now almost fully booked to capacity for H1 2021. This new facility will be run at the same high standard as our QMB site, and volunteers will be expertly supervised by our highly trained nurses and doctors in a safe and controlled clinical environment.”

Interested in becoming a volunteer?

If you are interested in being contacted and provided with details about future COVID-19 human challenge study research, please leave your contact details at www.UKCovidChallenge.com.

hVIVO recruits many of its volunteers for its challenge study clinical trials through its dedicated volunteer recruitment website, www.flucamp.com. By volunteering to take part in one of our studies in a safe, controlled, clinical environment under expertly supervised conditions you are playing your part to further medical research and help increase the understanding of respiratory illnesses.

Click to view all articles for the EPIC:
Or click to view the full company profile:
Facebook
Twitter
LinkedIn
Open Orphan Plc

More articles like this

Open Orphan Plc

Open Orphan appoints Yamin ‘Mo’ Khan as Chief Executive Officer

Open Orphan plc (LON:ORPH), a rapidly growing specialist contract research organisation (CRO) and world leader in testing infectious and respiratory disease products using human challenge clinical trials, announced today the appointment of Yamin ‘Mo’ Khan as Chief Executive Officer

Open Orphan Plc

Potential RSV vaccine achieves regulatory step in US

The US Food and Drug Administration (FDA) has granted breakthrough therapy designation for a vaccine candidate for respiratory syncytial virus (RSV). Bavarian Nordic’s MVA-BN RSV was granted the designation, which is designed to expedite the development

Open Orphan Plc

Open Orphan FDA Breakthrough Designation for Big Pharma RSV candidate

Open Orphan plc (LON:ORPH), a rapidly growing specialist contract research organisation (CRO) and world leader in testing infectious and respiratory disease products using human challenge clinical trials, noted today the announcement dated 14 February 2022 from Bavarian Nordic A/S (OMX: BAVA), reporting

Open Orphan Plc

The Drug development plan – Your roadmap to success

Each journey begins at a starting point, and we believe that few journeys are as exciting as developing a drug. In order to succeed and reach your destination, you need a solid roadmap, the drug development

Open Orphan Plc

Open Orphan launch STRiVE project a remarkable success

Open Orphan plc (LON:ORPH), a rapidly growing specialist contract research organisation (CRO) and world leader in testing infectious and respiratory disease products using human challenge clinical trials, announces that hVIVO, a subsidiary of Open Orphan plc, has recently launched

Open Orphan Plc

What is malaria?

Malaria is often quoted as the most common disease in all human history. With the earliest recorded cases are estimated to have been around 10,000 years ago, when a small plasmodium parasite made a jump across

Open Orphan Plc

Omicron and Long COVID: What we know so far

As the Omicron variant of the coronavirus continues to sweep across the United States, another important question has emerged for scientists worldwide: Will more transmission equal more long COVID cases? The rate of hospitalization has also

Open Orphan Plc

Pharmacokinetics Course

Pharmacokinetics (PK) is generally referred to as ‘what the body does to the drug’ versus ‘what the drug does to the body’ (pharmacodynamics [PD]). Pharmacokinetics describes the fate, or time course, of an administered drug within

Open Orphan Plc

Open Orphan launch new malaria human challenge

Open Orphan plc (LON:ORPH), a rapidly growing specialist contract research organisation (CRO) and world leader in vaccine and antiviral testing using human challenge clinical trials announces that further to the announcement on 9 August 2021, hVIVO, a subsidiary

Open Orphan Plc

RSV vaccines & treatments

The Challenge Respiratory syncytial virus (RSV) is the single most important cause of lower respiratory tract infection (LRTI) in infants and young children worldwide and can cause LRTI in elderly and immunocompromised patients; it is associated

Open Orphan Plc

FluCamp 2021 Year in Review

Open Orphan (LON:ORPH) was founded in 2017, with the goal of rapidly building Europe’s leading pharma services company by a management team with extensive industry and financial expertise. The company comprises of two commercial specialist CRO